Abalos Therapeutics GmbH

📍 Düsseldorf, Germany👥 19 employees💰 Last funded Jul 2022
Biotechnology Research🌐 abalos-tx.com
Website LinkedIn
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.
4
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
4
Investor activity2019–2022 · investors recorded per year
201922021120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Abalos Therapeutics GmbH?
Abalos Therapeutics GmbH has 4 investors on record on gritt.io.
When did Abalos Therapeutics GmbH last raise funding?
The most recent investment in Abalos Therapeutics GmbH recorded on gritt.io was in July 2022.
What industry is Abalos Therapeutics GmbH in?
Abalos Therapeutics GmbH operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Abalos Therapeutics GmbH based?
Abalos Therapeutics GmbH is headquartered in Düsseldorf, Germany.